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There is evidence that the platelet-activating factor receptor (PAFR) is involved in the clearance of apoptotic cells by macrophages,
and that this is associated with anti-inﬂammatory phenotype. Our group has previously shown that coinjection of a large number
of apoptotic cells can promote tumor growth from a subtumorigenic dose of melanoma cells. Here, we studied the involvement
of the PAFR in the tumor growth promoting eﬀect of apoptotic cells. A sub-tumorigenic dose of melanoma cells (Tm1) was
coinjected with apoptotic Tm1 cells, subcutaneously in the ﬂank of C57Bl/6 mice, and the volume was monitored for 30 days.
Animals received the PAFR antagonists, WEB2170 or PCA4248 (5mg/kg body weight) or vehicle, by peritumoral daily injection
for 5 days. Results showed that PAFR antagonists signiﬁcantly inhibited the tumor growth induced by the coinjection of a sub-
tumorigenic dose of melanoma cells together with apoptotic cells. This was accompanied by inhibition of early neutrophil and
macrophage inﬁltration. Addition of (platelet-activating factor) to this system has no signiﬁcant eﬀect. PAFR antagonists did not
aﬀect the promoting eﬀect of carrageenan. We suggest that the recognition of apoptotic cells by phagocytes leads to activation of
PAFR pathways, resulting in a microenvironment response favorable to melanoma growth.
1.Introduction
Several studies have shown the importance of tumor mi-
croenvironment during several phases of tumor progression
[1, 2]. The presence of inﬂammatory inﬁltrate in the tumor
microenvironment, consisting mainly of macrophages, neu-
trophils, and lymphocytes, contributes to tumor growth by
productionandsecretionofgrowthfactors,metaloproteases,
proangiogenic factors, cytokines, and chemokines [3].
Platelet-activating factor (PAF) is a potent phospholipid
mediator which plays a major role as a primary and a sec-
ondary messenger involved in cell-to-cell communication
[4]. The PAF receptor (PAFR) is a G-protein-coupled recep-
tor present in the plasma and nuclear membrane of ma-
crophages and other cell types [5]. Aside the key role of
macrophages in innate and adaptive immunity, they are also
responsible for the clearance of dying cells. This is achieved
through a group of scavenger receptors present in the plasma
membrane of macrophages with CD36 being among the
best studied. More recently, it was shown that PAFR is also
involved in the phagocytic removal of dying cells. De
Oliveira et al. [6] showed that phagocytosis of apoptotic
cells is increased compared to viable cells, and that this is
reversed by a PAFR antagonist. Phagocytosis of apoptotic
cells by macrophages is known to induce their polarization
towards a suppressive phenotype, with the production of
anti-inﬂammatory cytokines and mediators [7]. This is par-
ticularly relevant in the case of tumors where macrophages
polarization by apoptotic cells would create an immuno-
suppressive environment favoring tumor growth. It was2 Mediators of Inﬂammation
reported that murine melanoma growth was reduced by
treatment with a PAFR antagonist, and when combined with
chemotherapy, it increased survival time [8]. Taken together,
these results suggest that during tumor growth, clearance of
apoptotic cells suppresses tumor macrophages which favor
tumor growth, and that this involves PAFR expressed in the
macrophages plasma membrane.
Correa et al. [9] clearly demonstrated that apoptotic cells
injected together with a sub-tumorigenic dose of melanoma
cells promote tumor growth. Here we investigate whether
this eﬀect due to apoptotic cells is dependent on PAFR.
2.MaterialandMethods
2.1. Cell Culture, Reagents, and Proliferation Assay. The mu-
rine melanoma cell line Tm1 [10] was cultured in RPMI pH
6.9 (Gibco, Carlsbad, CA) supplemented with 5% fetal bo-
vineserum(Gibco,Carlsbad,CA)at37◦Cinahumidiﬁedat-
mosphere of 5% CO2 and 95% air. Carrageenan was pur-
chased from Sigma (St. Louis, MO), WEB2170 from Boeh-
ringer Ingelheim (Germany), PCA4248 from Tocris Bios-
cience (USA), and PAF from Cayman Chemical (Ann Arbor,
MI).
2.2. Tumorigenicity Assays. As previously described by Bachi
et al. [11], 2 × 107 Tm1 cells/mL were submitted to
γ-irradiation (200Gy) and to induced apoptosis, using
Gammacell 300 Elan (Nordion International, Inc., Ontario,
Canada), and a concentration of 2 × 104 viable Tm1 cells/mL
was separated. After the irradiation procedure, both cell
suspensions were centrifuged and suspended in PBS, and
then 50μLo fe a c hs o l u t i o n( 1× 103 viable cells plus 1 × 106
apoptotic cells) were mixed and co-injected subcutaneously
into the ﬂank of syngeneic 6- to 8-week-old C57Bl/6 female
mice. To assess the eﬀect of carrageenan on tumor progres-
sion, animals were co-injected with a mixture of 103 viable
Tm1 cells (50μL) and 0.1% carrageenan. Animals were kept
under 12-hour daylight cycles, without food restriction and
checked daily for tumor development. Each experimental
group consisted of at least ﬁve animals. Tumor growth was
monitored three times per week, and tumor volume was
determined as follows: [(maximum diameter) × (minimum
diameter)2]/ 2[ 12]. Mice with a subcutaneous mass larger
than 20mm3 were considered positive for the presence of
tumors.
2.3. Immunohistochemistry Analysis. Mice were sacriﬁced
according to institutional guidelines, and subcutaneous
tissue corresponding to the site of co-injection was excised
at diﬀerent time points after injection (6h, 24h and 72h).
Hematoxylin-stained sections were used in the immunohis-
tochemistry analysis for detection of neutrophils (myeloper-
oxidase-speciﬁc antibody, Santa Cruz, CA) and macrophages
(F4/80-speciﬁc antibody, Abcam, Cambridge, MA). Sections
were visualized on a Zeiss Axioskop 40 microscope; images
were captured using a Sony Cybershot camera (3.3 megapix-
els) and were analyzed on a MetaVue Imaging System v.6.1
(Molecular Devices Corporation, Sunnyvale, CA) for cell
counts.
2.4. In Vivo Treatment with PAF or PAF Receptor Antagonists.
Platelet-activating factor (PAF) was used in diﬀerent con-
centrations (1μg, 10μg, and 100μg), diluted in sterile PBS
and injected with a sub-tumorigenic dose of Tm1 melanoma
cells (103 cells). Animals injected with γ-irradiated Tm1 cells
(106 cells), or carrageenan and sub-tumorigenic dose of Tm1
melanoma cells (103 cells), were treated daily with 10μgo f
PAFinﬁvedoses(100μL),inthesamesiteastumorinjection
(termed peri-tumoral), the ﬁrst dose was given together
with tumor cells. The PAF receptor antagonists WEB2170
and PCA4248 were used in a concentration of 5mg/kg
of weight for each mouse, and the treatment program
consisted of ﬁve peri-tumoral daily injections (100μL), the
ﬁrst given together with the tumor cells. All experiments
were performed using groups of between ﬁve and ten, six-
to-eight-week old female mice. Control groups received
either injections of PBS or a sub-tumorigenic dose of Tm1
melanoma cells (103 cells), according to the type of exper-
iment (see Section 3 and ﬁgure legends).
2.5. Statistical Analysis. The data are expressed as the mean
± SD. Nonpaired nonparametric Student’s t-test was used
to analyze diﬀerences between the means, using the InStat
software package. The signiﬁcance level was established at
P<0.05.
3. Results
In a previous work we have established a protocol where the
co-injection of a sub-tumorigenic dose of melanoma cells
(103), together with apoptotic cells (106), or carrageenan,
promoted melanoma growth [11]. Here we used the same
model to investigate the involvement of PAFR. Animal
groups submitted to either co-injection (106 γ-irradiated
tumor cells and 103 viable tumor cells) or injection of carra-
geenanand103 viabletumorcellsweretreatedwiththeselec-
tivePAFRantagonistsWEB2170orPCA4248.Figure 1shows
that treatment with WEB2170 (Figure 1(a)) or PCA4248
(Figure 1(b)) reduced tumor progression, suggesting that
the PAFR plays an important role in growth of a sub-
tumorigenic dose of melanoma cells induced by a large
number of apoptotic cells. Injection of the classic inﬂamma-
tory agent, carrageenan, also promoted the growth of a sub-
tumorigenic dose of melanoma cells, as previously reported;
however, the treatment with PAFR antagonists did not aﬀect
tumor growth (Figure 1(c)). These results suggest that PAFR
contributes to the growth of a sub-tumorigenic dose of
tumor cells associated with co-injection of apoptotic cells.
To evaluate if PAF alone was able to promote the growth
of a sub-tumorigenic dose of melanoma cells, three diﬀerent
doses of PAF (1μg, 10μg, and 100μg) were injected together
with 103 viable tumor cells. We could not observe tumor
growth even up to sixty days following the injection (data
not shown).Mediators of Inﬂammation 3
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Figure 1: PAFR antagonists reduce melanoma growth associated with a massive number of apoptotic cells. The treatment of C57Bl/6 mice
with PAFR antagonists showed a signiﬁcant reduction in the melanoma growth (103 Tm1 viable cells) induced by apoptotic cells (106 γ-
irradiated Tm1 cells, (a) and (b)) but not by carrageenan (0.1% (c)). The animals were treated with PBS or PAFR antagonists (WEB2170
(WEB, (a)) or PCA4248 (PCA, (b) and (c)) 5mg/kg body weight)) by peritumor daily injections during 5 days. All experiments were
performed using groups of 5 to 10 mice, which were considered harboring tumors when the subcutaneous mass reached 20mm3 (palpable
tumor). ∗Denotes statistical signiﬁcance (P<0.05) using nonpaired nonparametric Student’s t-tests.
Next, we evaluated if injection of PAF would modify
the tumor growth induced by co-injection of apoptotic cells
or carrageenan. Animals co-injected with apoptotic cells
(Figure 2(a)), or with carrageenan and 103 viable tumor cells
(Figure 2(b)) ,w e r et r e a t e df o rﬁ v ed a y sw i t h1 0μg of PAF.
Nosigniﬁcantstatisticaldiﬀerencewasobservedinthetumor
growth in these conditions.
Subcutaneous tissues from animals co-injected with
apoptotic cells (106) and viable melanoma cells (103)a n d
treated with PAF receptor antagonist PCA4248 or PBS
(control) were surgically removed after 6h, 24h, and 72h of
the co-injection to evaluate the inﬁltration of macrophages
and neutrophils by immunohistochemical analysis for MPO
expression, as marker of neutrophils and F4/80, as marker
of macrophages. Analyses showed a signiﬁcant reduction
in the expression of myeloperoxidase (MPO), 6h and 24h
after co-injection in the group of animals that were treated
with PCA4248. Seventy-two hours after co-injection, the
expression of MPO decreased and was similar in both groups
of animals (Figure 3(a)). Regarding macrophage inﬁltration,
in contrast to neutrophils, the number of cells expressing
F4/80 did not diﬀer between the groups at 6h and 24h
after co-injection. However, after 72h of co-injection the
analysis showed a signiﬁcant reduction of F4/80 expression
inanimalstreatedwithPCA4248incomparisontothegroup
of animals treated with PBS (Figure 3(b)).
4. Discussion
According to our previous data, the injection of a large num-
ber of apoptotic cells creates a tumor microenvironment that
favors the growth of a sub-tumorigenic dose of melanoma
cells [9, 11]. During the process of apoptosis, diﬀerent
lipids, particularly phospholipids, which are exposed at the
cell membrane are oxidized. Oxidised moieties present in4 Mediators of Inﬂammation
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Figure 2: PAF does not aﬀect melanoma progression induced by apoptotic cells or carrageenan. Melanoma growth (103 viable Tm1 cells)
inducedbyapoptoticcells(106 γ-irradiatedTm1cells,(a))orcarrageenan(0.1%,(b))inC57Bl/6micedidnotshowanystatisticaldiﬀerence
between the treatment with PBS or PAF (10μg) given by peritumor injection daily for 5 consecutive days.
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Figure 3: Treatment with PAFR antagonist reduces neutrophil and macrophage inﬁltration. The inhibition of PAFR using PCA4248 (PCA)
results in reduced neutrophil and macrophage inﬁltration in mice submitted to coinjection of apoptotic cells (106 γ-irradiated Tm1) and a
subtumorigenic dose of Tm1 melanoma cells (103 viable cells). Subcutaneous tissues from animals treated with PBS or PCA4248 (PCA), for
5 consecutive days, were surgically removed 6, 24 and 72h after coinjection and processed for immunohistochemistry analysis using speciﬁc
antibodies against myeloperoxidase (antigen expressed mainly by neutrophils, (a)) and F4/80 (cell marker by macrophages, (b)). ∗Denotes
statistical signiﬁcance (P<0.05) using nonpaired nonparametric Student’s t-tests.
apoptotic cells may be recognized by scavenger receptors,
such as CD36, expressed in phagocytes, and may induce the
clearanceofdyingcells.ThePAFRisalsoinvolvedsinceithas
been shown that PAFR antagonists inhibit the phagocytosis
of apoptotic and necrotic cells by macrophages in vitro [6].
Here we showed that the speciﬁc inhibition of PAFR by
the antagonist WEB2170 reduced signiﬁcantly the growth of
a sub-tumorigenic dose of melanoma cells associated with
a large number of apoptotic cells. Conﬁrming the role of
this receptor in promoting tumor growth, the inhibition of
PAFR by a second antagonist (PCA4248) partially abrogated
the tumor growth associated with the apoptotic cells. The
two antagonists used in this study both reduced signiﬁcantly
the tumor growth, but PCA4248 was more eﬀective than
WEB2170. Although the two antagonists are more or less
equipotent at a molar ratio, the half time of duration of
action could be diﬀerent for each compound. These data
suggest that interaction of PAF-like molecules on the surface
of apoptotic cells with PAFR in cells present in the tumor
microenvironment exerts an important modulation during
the initial stages following tumor cell implantation.
We also observed that co-injection of PAF with a sub-tu-
morigenic dose of melanoma cells does not have the growth
promoting eﬀect of the apoptotic cells (data not shown).
Moreover, addition of PAF to the co-injection model did
not aﬀect the tumor growth. Although PAF is an unstableMediators of Inﬂammation 5
compound, the high dose that was injected (10μg) in the
site of the tumor for ﬁve consecutive days should be eﬀective.
Fernandez-Gallardo et al. [13] reported that even ten-times
less PAF, injected into mouse skin, was able to induce plasma
extravasation.
These results show that activation of the PAFR by ex-
ogenous PAF does not reproduce the eﬀect of the apoptotic
cells and suggest that the recognition of other moieties, be-
sides PAF-like ones, present on apoptotic cells is required. It
has been shown by Rios et al. [14] that for optimal uptake
of oxLDL by human monocytes/macrophages both the scav-
enger receptor CD36 and PAFR are required. In subsequent
work, these authors also demonstrated that following phago-
cytosis of apoptotic cells, PAFR colocalizes with CD36 in the
plasma membrane of macrophages. Moreover, in HEK293
cells transfected with PAFR, CD36, or both, apoptotic cells
onlyinduceIL-8productionwhenbothreceptorsarepresent
[15]. This allows the speculation that engagement of scav-
enger receptors by apoptotic cells recruits PAFR to speciﬁc
membrane microdomains, and that the signaling elicited by
each receptor converges to activate gene transcription with
the results being production of cytokines which modify the
microenvironment.
The microenvironment surrounding the tumor mass will
contain proliferating tumor cells, many of which will be un-
dergoing apoptosis and necrosis, along with several host
components that include stromal cells, and a characteristic
inﬂammatory inﬁltrate associated with constant tissue re-
modeling [16]. Stromal cells, which are mainly comprised
of ﬁbroblasts, macrophages, neutrophils, eosinophils, mast
cells, lymphocytes, dendritic cells and endothelial cells, form
a part of the tumor microenvironment which supports and
regulates the growth of tumor cells [17]. Interactions be-
tween tumor and stromal cells can occur via cell-cell inter-
actions, or by cytokine- or chemokine-mediated signaling
[18]. We propose here that these interactions also involve
PAFR-mediated signaling. Immunochemistry assays on tu-
mors from mice injected with apoptotic cells and a sub-tu-
morigenic dose of melanoma cells showed that treatment
with the PAFR antagonist reduced neutrophil inﬁltration
in the ﬁrst 24h of tumor injection and after three days,
inﬁltration of macrophages. It can be speculated that the
inhibitionofmacrophageinﬁltrationbythePAFRantagonist
at the early phase of tumor/apoptotic cell co-injection would
reduce the level of suppressor molecules in the tumor mi-
croenvironment favoring the inhibition of tumor progres-
sion observed with PAFR antagonist treatment. Regarding
neutrophils,morestudiesareneededtounderstandtheirrole
in tumor growth.
During tumor development a large number of tumor
cells become apoptotic or necrotic. These dead cells are re-
moved through phagocytosis by neighboring and inﬂamma-
tory cells, mainly macrophages. It was demonstrated that
phagocytosis of apoptotic cells reduces macrophage activa-
tion [7]. As a consequence, the presence of apoptotic cells
can favor tumor growth by suppressing macrophage func-
tions. The PAFR has been shown to participate in the pha-
gocytic removal of apoptotic cells by macrophages, and
this is followed by production of suppressor molecules
[6]. It has been also shown that PAFR antagonists inhibit
melanoma growth [8]. Here we demonstrate that apoptotic
cells can promote tumor growth through PAFR-dependent
mechanisms.
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